Spevigo

[anonymous]

thinking of joining up. any take on this? thanks.

 

[anonymous]

It’s a tough road. Ultra rare so not a lot of cases out there. Hopefully can find ways to sustain the division.

 

[anonymous]

Run

 

[anonymous]

If you aren't coming from a rare disease background and in this case ultra rare then its a tough go. Patients are extremely difficult to find. Derms are great to call on. If you have double digit patients then you're a rock star and fortunate.

 

[anonymous]

thinking of joining up. any take on this? thanks.

It’s going to depend on the patience of Germany if this is a viable product to support. Sales goals are not being met but crazy budgets factor into that. If your sales don’t pay for your salaries you don’t stick around long.

 

[anonymous]

Any info on the Phoenix position?

 

[anonymous]

Any info on the Phoenix position?

It's in Phoenix.

 

[anonymous]

Any info on the Phoenix position?

Germans are LIKELY to stay patient due to the molecule’s future indications.
The territory is large, including Vegas. If your family situation allows (no little ones at home), and you are willing to hustle, you can succeed, and make a name for yourself in this small division.

 

[anonymous]

Germans are LIKELY to stay patient due to the molecule’s future indications.
The territory is large, including Vegas. If your family situation allows (no little ones at home), and you are willing to hustle, you can succeed, and make a name for yourself in this small division.

Thank you! That is actually very helpful.

 

[anonymous]

What are the chances we just sell this, a la Skyrizi, to a company that's devoted to dermatology? I'd like to join, but I'm worried BI doesn't understand derm or rare.

 

[anonymous]

What are the chances we just sell this, a la Skyrizi, to a company that's devoted to dermatology? I'd like to join, but I'm worried BI doesn't understand derm or rare.

They absolutely do not understand rare disease. Look what they’re doing to the ILD division with the metric-driven process they’ve switched to.
All they’ve done is manage to drive people away, and that’s not going to stop.

 

[anonymous]

They absolutely do not understand rare disease. Look what they’re doing to the ILD division with the metric-driven process they’ve switched to.
All they’ve done is manage to drive people away, and that’s not going to stop.

What a stupid response. Spevigo is a much different marketplace.

 

[anonymous]

They absolutely do not understand rare disease. Look what they’re doing to the ILD division with the metric-driven process they’ve switched to.
All they’ve done is manage to drive people away, and that’s not going to stop.

The metrics is a global initiative throughout business units. You just get it done. Quit whining...it's not that hard princess.

 

[anonymous]

The metrics is a global initiative throughout business units. You just get it done. Quit whining...it's not that hard princess.

What a stupid response. OFEV is a much different marketplace.

 

[anonymous]

Just applied for sales job. Drug looks great. What’s the challenge? Why are docs using it on all patients? Cost? Looked at as the last resort for worst cases? Prior auths hard?

 

[anonymous]

Why aren’t I meant

 

[anonymous]

Any chance the goal will be adjusted by years’ end?

 

[anonymous]

Any chance the goal will be adjusted by years’ end?

Budget is budget, so goal will not be adjusted. However, leadership may make the field team whole from an IC perspective. They did similar with Cyltezo and that drug is a dog.

Bigger issue is the inability to accurately make any sales goal in the specialty market. Leadership continues to make ‘ambitious’ budgets with significant stretch, when the numbers are reached, who pays the price? Well this year majority of the company will. VPR will barely be over 90% and IC checks will also suffer.

There are other companies out there that know the specialty space better and have effective leadership. Muddle through crap at BI until you find something new. The grass IS greener.

 

[anonymous]

Any chance the goal will be adjusted by years’ end?

I'll be interested about 2025 and what the overall status is.

 

[anonymous]

Any chance the goal will be adjusted by years’ end?

Goal is never adjusted down you idiot. Only up. And considering how poorly Spevigo has performed this year (just like previous years) it’s likely that this drug has little time left.BI should sell the asset off to a smaller biotech and let them try to resuscitate it. Take some money now to recoup the loss. Move existing sales force over to the mental health (if that even launches) digital therapeutic and hope for the best.